Form 10-QT - Transition reports [Rule 13a-10 or 15d-10]:
SEC Accession No. 0000827871-15-000012
Filing Date
2015-02-17
Accepted
2015-02-17 16:05:43
Documents
10
Period of Report
2014-12-31

Document Format Files

Seq Description Document Type Size
1 10-QT egrx_q1x2015.htm 10-QT 827820
2 EXHIBIT 31.1 exhibit311q12015.htm EX-31.1 11092
3 EXHIBIT 31.2 exhibit312q12015.htm EX-31.2 11072
4 EXHIBIT 32.1 exhibit321q12015.htm EX-32.1 5772
  Complete submission text file 0000827871-15-000012.txt   3842873

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT egrx-20141231.xml EX-101.INS 440878
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT egrx-20141231.xsd EX-101.SCH 26823
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT egrx-20141231_cal.xml EX-101.CAL 40593
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT egrx-20141231_def.xml EX-101.DEF 83107
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT egrx-20141231_lab.xml EX-101.LAB 338238
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT egrx-20141231_pre.xml EX-101.PRE 179904
Mailing Address 50 TICE BOULEVARD, SUITE 315 WOODCLIFF LAKE NJ 07677
Business Address 50 TICE BOULEVARD, SUITE 315 WOODCLIFF LAKE NJ 07677 201-326-5300
EAGLE PHARMACEUTICALS, INC. (Filer) CIK: 0000827871 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-QT | Act: 34 | File No.: 001-36306 | Film No.: 15622222
SIC: 2834 Pharmaceutical Preparations